Bupropion 100 mg Sustained Release (SR) Tablets — Generic For Wellbutrin SR — Camber

These highlights do not include all the information needed to use BUPROPION HYDROCHLORIDE EXTENDED-RELEASE TABLETS (SR) safely and effectively. See full prescribing information for BUPROPION HYDROCHLORIDE EXTENDED-RELEASE TABLETS (SR).

BUPROPION HYDROCHLORIDE extended-release tablets (SR), for oral use

Initial U.S. Approval: 1985

Warning: Suicidal Thoughts And Behaviors

See full prescribing information for complete boxed warning.

5.1)

5.1)

Indications And Usage

Bupropion hydrochloride extended-release tablets (SR) are an aminoketone antidepressant, indicated for the treatment of major depressive disorder (MDD). (

1)

Dosage And Administration

(2.1)

(2.1,

5.3)

(2.1)

(2.1)

(2.1)

(2.1)

(2.2,

8.7)

(2.2,

8.7)

(2.3,

8.6)

Dosage Forms And Strengths

Tablets: 100 mg, 150 mg, 200 mg. (

3)

Contraindications

4,

5.3)

(4,

5.3)

4,

5.3)

4,

7.6)

4,

5.8)

Warnings And Precautions

• Neuropsychiatric adverse events during smoking cessation: Postmarketing reports of serious or clinically significant neuropsychiatric adverse events have included changes in mood (including depression and mania), psychosis, hallucinations, paranoia, delusions, homicidal ideation, aggression, hostility, agitation, anxiety, and panic, as well as suicidal ideation, suicide attempt, and completed suicide. Observe patients attempting to quit smoking with bupropion for the occurrence of such symptoms and instruct them to discontinue bupropion and contact a healthcare provider if they experience such adverse events. ( 5.2)
• Seizure risk: The risk is dose-related. Can minimize risk by gradually increasing the dose and limiting daily dose to 400 mg. Discontinue if seizure occurs. ( 4, 5.3, 7.3)
• Hypertension: Bupropion hydrochloride extended-release tablets (SR) can increase blood pressure. Monitor blood pressure before initiating treatment and periodically during treatment. ( 5.4)
• Activation of mania/hypomania: Screen patients for bipolar disorder and monitor for these symptoms. ( 5.5)
• Psychosis and other neuropsychiatric reactions: Instruct patients to contact a healthcare professional if such reactions occur. ( 5.6)
• Angle-closure glaucoma: Angle-closure glaucoma has occurred in patients with untreated anatomically narrow angles treated with antidepressants. ( 5.7)

• Neuropsychiatric adverse events during smoking cessation: Postmarketing reports of serious or clinically significant neuropsychiatric adverse events have included changes in mood (including depression and mania), psychosis, hallucinations, paranoia, delusions, homicidal ideation, aggression, hostility, agitation, anxiety, and panic, as well as suicidal ideation, suicide attempt, and completed suicide. Observe patients attempting to quit smoking with bupropion for the occurrence of such symptoms and instruct them to discontinue bupropion and contact a healthcare provider if they experience such adverse events. ( 5.2)
• Seizure risk: The risk is dose-related. Can minimize risk by gradually increasing the dose and limiting daily dose to 400 mg. Discontinue if seizure occurs. ( 4, 5.3, 7.3)
• Hypertension: Bupropion hydrochloride extended-release tablets (SR) can increase blood pressure. Monitor blood pressure before initiating treatment and periodically during treatment. ( 5.4)
• Activation of mania/hypomania: Screen patients for bipolar disorder and monitor for these symptoms. ( 5.5)
• Psychosis and other neuropsychiatric reactions: Instruct patients to contact a healthcare professional if such reactions occur. ( 5.6)
• Angle-closure glaucoma: Angle-closure glaucoma has occurred in patients with untreated anatomically narrow angles treated with antidepressants. ( 5.7)

5.2)

4,

5.3,

7.3)

5.4)

5.5)

5.6)

5.7)

Adverse Reactions

Most common adverse reactions (incidence ≥5% and ≥2% more than placebo rate) are: headache, dry mouth, nausea, insomnia, dizziness, pharyngitis, constipation, agitation, anxiety, abdominal pain, tinnitus, tremor, palpitation, myalgia, sweating, rash, and anorexia. (

6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Annora Pharma Private Limited at 1-866-495-1995 or FDA at 1-800-FDA-1088 or

www.fda.gov/medwatch.

Drug Interactions

7.1)

7.2)

7.2)

5.3,

7.3)

7.4)

7.6)

7.7)

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.

Revised: 1/2026